demonstrated that CPLX1 may be a biomarker and therapeutic target for gastric cancer recurrence by transcriptomics and ex vivo experiments on surgically resected specimens from 16 UICC stage III gastric cancer patients who underwent radical gastrectomy and adjuvant oral fluoropyrimidine monotherapy (6). The gene discussed is CPLX1; the disease is gastric cancer.